Tag: Bladder Cancer

Among patients with muscle-invasive urothelial carcinoma (MIUC), the presence of detectable circulating tumor DNA (ctDNA) after surgery may identify those who are likely to benefit from adjuvant immunotherapy with the immune checkpoint inhibitor atezolizumab (Tecentriq). The finding comes from a new analysis of data from the ImVigor010 trial, which had failed to reach its primary

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates or cancer control? Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer. The

One of the main risk factors for non-melanoma skin cancer (NMSC), the most common cancer worldwide, is solar ultraviolet radiation. A new Journal of the European Academy of Dermatology and Venereology study has found that different outdoor professions carry different risks for NMSC. In the study of 563 participants (47% women) consisting of 348 outdoor

Columbia University Irving Medical Center (CUIMC) and NewYork-Presbyterian researchers have created patient-specific bladder cancer organoids that mimic many of the characteristics of actual tumors. The use of organoids, tiny 3-D spheres derived from a patient’s own tumor, may be useful in the future to guide treatment of patients. The study was published today in the